Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Nicole Gannon"'
Autor:
Karan Seegobin, Muhamad A. Moustafa, Nicole Gannon, Katelyn Keller, Jacquelyn Hastings, Vivek Gupta, Han W. Tun, Liuyan Jiang
Publikováno v:
Clinical Case Reports, Vol 9, Iss 3, Pp 1610-1614 (2021)
Abstract IgG4‐related disease (IgG4RD) with intracranial involvement is rare. We report a 56‐year‐old male who had an excellent response to rituximab and dexamethasone after going undiagnosed for 5 years. After 3 years of rituximab maintenance,
Externí odkaz:
https://doaj.org/article/063b9b1ba7f040ac801a35fb91a6c24f
Autor:
Megan Melody, Sangeetha Gandhi, Hollie Saunders, Zaid Abdel-Rahman, Jacquelyn Hastings, Paula Lengerke Diaz, Nicole Gannon, Tuan Truong, Matthew Hathcock, Arushi Khurana, Patrick Johnston, Stephen Ansell, Nora Bennani, Jonas Paludo, Jose Villasboas Bisneto, Yucai Wang, Allison Rosenthal, James Foran, Ernesto Ayala, Hemant S. Murthy, Vivek Roy, Januario E. Castro, Yi Lin, Mohamed A. Kharfan-Dabaja
Publikováno v:
Leukemia & Lymphoma. 63:1363-1368
Chimeric antigen receptor (CAR) T-cell therapy is effective in relapsed/refractory large B-cell lymphoma and results in a unique toxicity profile, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome. The
Autor:
Nicole Gannon, Liuyan Jiang, Jacquelyn Hastings, Han W. Tun, Katelyn Keller, Muhamad Alhaj Moustafa, Vivek Gupta, Karan Seegobin
Publikováno v:
Clinical Case Reports
Clinical Case Reports, Vol 9, Iss 3, Pp 1610-1614 (2021)
Clinical Case Reports, Vol 9, Iss 3, Pp 1610-1614 (2021)
IgG4‐related disease (IgG4RD) with intracranial involvement is rare. We report a 56‐year‐old male who had an excellent response to rituximab and dexamethasone after going undiagnosed for 5 years. After 3 years of rituximab maintenance, he has n
Autor:
Hemant S. Murthy, James M. Foran, Tuan Truong, Nicole Gannon, Eva Brandes, Mattia Novo, Paula A. Lengerke-Diaz, Allison C. Rosenthal, Vivek Roy, S. M. Ansell, Patrick B. Johnston, Gina Lange, Jonas Paludo, Yi Lin, Januario E. Castro, Mohamed A. Kharfan-Dabaja, Jose Villasboas Bisneto, N. Nora Bennani, Sangeetha Gandhi, Zaid Abdel Rahman, Breana Estby, Megan Melody, Ernesto Ayala, Han W. Tun
Publikováno v:
European journal of haematologyREFERENCES. 107(1)
Introduction Hypoalbuminemia is a known adverse prognostic factor in lymphomas. Yet, it is unknown if Axicabtagene Ciloleucel (axi-cel) overcomes the adverse prognostic impact of hypoalbuminemia in relapsed/refractory large B-cell lymphoma. Methods W
Autor:
Pramod Guru, Megan Melody, James M. Foran, Allison C. Rosenthal, Paula A Lengerke Diaz, Nicole Gannon, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Hemant S. Murthy, Vivek Roy, Hollie Saunders, Zaid Abdel Rahman, Han W. Tun, Januario E. Castro
Publikováno v:
Hematology/Oncology and Stem Cell Therapy, Vol 14, Iss 2, Pp 141-146 (2021)
Objective/Background Chimeric antigen receptor (CAR) T-cell is an effective therapy in relapsed/refractory large B-cell lymphomas that, due to its unique toxicities, often requires escalation of care to the intensive care unit (ICU) setting. C-reacti
Autor:
Jennifer R. Arthurs, Martin Gibbs, Sikander Ailawadhi, Mark R. Waddle, Eva Gupta, Nicole Gannon, Tanya S. Kakar, Myra A. Irvin, Deborah Fischer
Publikováno v:
Chemotherapy. 62:295-300
Oxaliplatin is one of the most commonly used drugs for patients with colorectal cancer. It has rarely been associated with disseminated intravascular coagulation (DIC) with only 3 previously reported cases. In all those instances, the patients had st
Autor:
Januario E. Castro, Zaid Abdel Rahman, Mattia Novo, Muhamad Alhaj Moustafa, Hemant S. Murthy, Allison C. Rosenthal, Paula A Lengerke Diaz, Han Tun, Mohamed A. Kharfan-Dabaja, Patrick B. Johnston, Eva Brandes, Jonas Paludo, Jose Villasboas Bisneto, Stephen M. Ansell, Nora N Bennani, Ernesto Ayala, Nicole Gannon, James M. Foran, Gina Lange, Yi Lin, Tuan Truong, Sangeetha Gandhi, Megan Melody, Breanna Estby
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S261-S262
Background Axi-cel is an autologous anti-CD19 chimeric antigen receptor T-cell therapy approved for treatment of CD19+ relapsed/refractory large B-cell lymphoma. Axi-cel is associated with unique toxicities, namely cytokine release syndrome (CRS) and
Autor:
Zaid Abdel-Rahman, Allison C. Rosenthal, Paula A Lengerke Diaz, Megan Melody, Nicole Gannon, Ernesto Ayala, Vivek Roy, Mohamed A. Kharfan-Dabaja, Pramod Guru, Han Tun, Hollie Saunders, James M. Foran, Hemant S. Murthy, Januario E. Castro
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S270-S271
Background Axicabtagene ciloleucel (Axi-cel) is an autologous chimeric antigen receptor (CAR) T-cell therapy which is effective in relapsed/refractory (R/R) anti-CD19 B-cell leukemia and lymphomas. Axi-cel is associated with unique toxicities, includ
Autor:
Karan Seegobin, Han W. Tun, Mohamed A. Kharfan-Dabaja, Ricardo D. Parrondo, Bradford S. Hoppe, Muhamad Alhaj Moustafa, Ernesto Ayala, Liuyan Jiang, Nicole Gannon, Jacquelyn Hastings, David M. Menke
Publikováno v:
Journal of Clinical Oncology. 38:e20044-e20044
e20044 Background: Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg-type (PCDLBCL) is a rare lymphoma comprising 4% of all cutaneous lymphomas with an aggressive clinical course. We investigated disease characteristics and outcomes among patients
Autor:
Han W. Tun, Leyla Bojanini Molina, Mohamed A. Kharfan-Dabaja, Muhamad Alhaj Moustafa, Ricardo D. Parrondo, David M. Menke, Karan Seegobin, Nicole Gannon, Ernesto Ayala, Liuyan Jiang, Jacquelyn Hastings, Bradford S. Hoppe
Publikováno v:
Journal of Clinical Oncology. 38:e20036-e20036
e20036 Background: Hepatosplenic T cell lymphoma (HSTL) is a rare subtype of mature T cell lymphomas accounting for less than 1 percent of non-Hodgkin lymphomas. it has been associated with poor prognosis. It typically involves sinusoids in the splee